Danziten (nilotinib) — Highmark
Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML)
Preferred products
- generic nilotinib
Initial criteria
- adult patient with Ph+ CML (ICD-10: C92.1) AND ((CML in chronic or accelerated phase AND resistance or intolerance to prior therapy that included imatinib) OR newly diagnosed in chronic phase)
- member has experienced therapeutic failure or intolerance to plan-preferred, generic nilotinib